September 3, 2008
aCROnordic reports strong growth
The fiscal year 2007/2008 in aCROnordic ended very satisfactory as the company reports a revenue growth of 38% to 40.2 million DKK and a profit growth of 23% to 5.6 million DKK.
- I am pleased to say that we are performing above expectation. This is a successful reflection of the focus, initiative, and extremely hard work of every one in the company, says Søren Strøh, CEO of aCROnordic.
The strong financial performance comes from an increased and high level of activities, particularly in the area of clinical operations. The contract research organisation is successfully providing quality services to the local biotech, pharmaceutical, and medical device industry making aCROnordic one of the market’s leaders. Furthermore the company reports on significantly increased international activities and is now looking into further expansions in the Nordic area, striving to take market lead in this area as well.
In order to ensure continued growth and follow up of this year’s strong performance, aCROnordic is now working with a wider business concept as Development CRO embracing all the disciplines involved in drug and medical device development.